Cat. Number:

Anti-PGRPS抗體KL-7673R

Quantity size:

0.2ml

Concentration:

1mg/ml   Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.

Background:

The primary immune recognition is based on structures common among invading pathogens. Bacterial surface molecules, such as lipopolysaccharide (LPS) and peptidoglycan (PGN), are known to elicit immune reactions ranging from cytokine release to fever. Recently, a family of proteins called peptidoglycan recognition protein (PGRP) has been identified in mouse and human that binds to peptidoglycans expressed on Anti-PGRPS抗體Gram-positive bacteria. Peptidoglycan (PGN) is an essential cell wall component of virtually all bacteria and, thus, it is an excellent target for recognition by the eukaryotic innate immune system. The PGRPs (PGRP-L, PGRPS, PGRPIA, and PGRP-I-beta) define a new family of human pattern recognition molecules. PGRP-L is primarily expressed in the liver. Although liver is not considered a primary immune organ, liver participates in host defenses by producing acute phase proteins (by hepatocytes) in response to infections and by clearing microorganisms from blood. PGRPS is present in neutrophils and inhibits growth of Gram-positive bacteria and, therefore, may function as a neutrophil antibacterial protein. However, PGRPS may have another, as yet unidentified function because in humans it is expressed in the bone marrow 50–100 times higher than in neutrophils.

Also known as:

Peptidoglycan recognition protein 1; Anti-PGRPS抗體Peptidoglycan recognition protein; PGLYRP; PGLYRP1; PGRP; PGRP S; PGRP-PEN; PGRP-S; TAG7; TNFSF 3L; TNFSF3L; PGRP1_HUMAN.

Specificity:

Storage:

Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).

Application:

WB=1:100-500  ELISA=1:500-1000  IHC-P=1:100-500  IHC-F=1:100-500  IF=1:100-500   
Not yet tested in other applications. Anti-PGRPS抗體
Optimal working dilutions must be determined by the end user.